secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2025-08-20T23:59:59+00:00
Accession:  0001563880-25-000005
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics CFO Lisa Delfini to depart Aug 22; CEO to serve as interim principal financial officer
--------------------------------------------------------------------------------

- CFO Lisa Delfini will resign effective August 22, 2025; departure is not due to any disagreement with the company.
- CEO Jennifer L. Good will serve as interim principal financial officer until a permanent CFO is appointed.
- Delfini will receive separation benefits under the Executive Separation Benefits and Retention Plan, subject to a severance and release agreement.
- No details provided on search for permanent CFO or timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000156388025000005/0001563880-25-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000156388025000005/trvi-20250814.htm
  HTML page:      https://secwatch.observer/filing/0001563880-25-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer